Table 2. The basic characteristics of patients with iPAH and controls (healthy volunteers) are listed.
| iPAH (n = 8) | Controls (n = 11) | p value | |
| Age in years | 36.6 (37.4) ±9.9 (3.5), [21]–[50] | 36. 4(33.0) ±12.3 (3.7), [22]–[62] | 0.963 |
| F:M ratio n (%) | 8∶0 (100∶0) | 10∶1 (90.9∶9.1) | 0.381 |
| PAP mean [mmHg] | 54.5 (57.5) ±20.0 (10.0), [28–75] | ||
| PVR [dynes·s−1·cm−5] | 1425.0 (1505.0) ±582.1 (291.0), [706–1984] | ||
| CI [l/min/m2] | 3.7 (3.8) ±0.4 (0.1) | ||
| sRAGE [pg/ml] | 743.7 (401.9) ±672.9 (254.3), [123.9–1861.7] | 195.5 (130.8) ±130.9 (39.5), [51.0–441.1] | 0.017 |
| esRAGE [pg/ml] | 1391.1 (972.9) ±1073.2 (379.4), [280.0–3110.0] | 423.2 (399.4) ±197.1 (59.4), [210.0–750.0] | 0.009 |
| S100A9 [µg/ml] | 1.4 (0.8) ±1.7 (0.6), [0.5–5.6] | 0.9 (0.7) ±0.5 (0.1), [0.4–2.1] | 0.374 |
| HMGB1 [pg/ml] | 1419.4 (845.2) ±1614 (610.1), [381.5–5020.9] | 415.1 (410.6) ±207.0 (65.5), [80.6–833.3] | 0.067 |
Reported is mean (median) ± standard deviation (standard error mean), [range].
iPAH idiopathic pulmonary arterial hypertension, n number of patients, F:M ratio female to male ratio, PAPmean mean pulmonary artery pressure, PVR pulmonary vascular resistance; CI cardiac index, sRAGE soluble receptor for advanced glycation endproducts, esRAGE endogenous secretory receptor for advanced glycation endproducts, S100A9 member of S100 family of Ca+ binding proteins, HMGB1 high mobility group box1.